April 3rd 2025
A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One
View More
Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients
View More
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer
View More
Chemo Combo Increases Survival, Toxicity in Sensitive Relapsed SCLC
June 23rd 2014Cisplatin, etoposide, and irinotecan outperformed topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC) in a Japanese trial, though there was substantially increased toxicity with the regimen.
Necitumumab Yields Small Benefit in Squamous Cell Lung Cancer
June 6th 2014The addition of the anti-EGFR antibody necitumumab to gemcitabine-cisplatin chemotherapy resulted in a modest but significant benefit to patients with stage IV squamous cell non-small-cell lung cancer, according to results of the SQUIRE study presented at ASCO.
Bevacizumab Added to Erlotinib Increases PFS in NSCLC
June 6th 2014The addition of bevacizumab to erlotinib as first-line therapy yielded a significantly extended progression-free survival in patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC), according to a new phase II study.
Thoracic RT Yields Improved Survival in Extensive-Stage SCLC
June 5th 2014Thoracic radiotherapy along with prophylactic cranial irradiation (PCI) significantly prolonged progression-free and overall survival in patients with extensive-stage small-cell lung cancer, according to results of a new study presented at ASCO.
Onartuzumab Added No Benefit in MET-Amplified NSCLC
June 4th 2014The addition of the MET-targeting antibody onartuzumab to erlotinib added no benefit, and may have been detrimental, to patients with MET-amplified stage IIIb/IV metastatic non–small-cell lung cancer, according to a new phase III trial.
Addressing the Common Mystery of the Solitary Pulmonary Nodule
May 15th 2014To ultimately find what we are actually looking for, the invasive malignant nodule in a haystack of benign lesions, new strategies and qualitative and quantitative tools are needed to propel noninvasive evaluation of solitary pulmonary nodules into the 21st century.
Low-Dose Spiral CT Screening and Evaluation of the Solitary Pulmonary Nodule
May 15th 2014The number of lesions detected with low-dose CT, only some of which are early cancers, is so great that algorithms are being developed for more efficient evaluation and management of solitary pulmonary nodules. This article will discuss current tools, approaches, and concerns regarding patient care in this setting.
Amrubicin and Cisplatin Inferior to Irinotecan Regimen for Small-Cell Lung Cancer
April 23rd 2014A combination of amrubicin and cisplatin was inferior to irinotecan and cisplatin in chemotherapy-naïve patients with extensive disease small-cell lung cancer (SCLC) in a phase III trial conducted in Japan.
Meeting the Challenges of Centrally Located Non–Small-Cell Lung Cancer
March 15th 2014Surgery continues to advance with the availability of new technology, knowledge and skills gained through experience, and collaboration between specialties. Some tumors that were unresectable in years past are now resectable. Other tumors that we currently consider beyond our ability to remove may be conquered in the near future.
Invasive Staging and Aggressive Surgical Resection: Essential to Management of Central NSCLC
March 15th 2014In summary, central lung cancers, when appropriately staged, are optimally treated by surgical resection. Initial evaluation is best done by a multidisciplinary team, involving a trained thoracic surgeon.
Tobacco Control Since the 1964 Surgeon General's Report: Reflecting Back and Looking Forward
March 15th 2014We now have more tools than ever in the fight against tobacco-related death and disability, but unfortunately, there is not equal access to resources for smoking cessation, early lung cancer diagnosis, and treatment.
MicroRNA Test Could Improve Lung Cancer Screening Accuracy
February 4th 2014The use of a microRNA signature classifier assay was found to have high predictive, diagnostic, and prognostic value in a lung cancer screening trial in Italy. Adding the plasma microRNA test to low-dose CT screening reduced false positive rates.